Status:
RECRUITING
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
Lead Sponsor:
University of Central Florida
Conditions:
Cancer of Pancreas
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples....
Detailed Description
Pancreatic ductal adenocarcinoma (PDAC) is a neoplastic disease which accounts for "90% of pancreatic malignancies," and has a 5-year survival rate of only 9%. The dismal nature of the PDAC diagnosis,...
Eligibility Criteria
Inclusion
- 18 years old or older
- Pancreatic cancer patients
Exclusion
- Children may not register
- Persons who are unable to consent may not register
Key Trial Info
Start Date :
May 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06148298
Start Date
May 24 2023
End Date
May 1 2025
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Central Florida
Orlando, Florida, United States, 32816